Cite
HARVARD Citation
Wang, G. et al. (2023). Safety and immunogenicity of a bivalent SARS-CoV-2 recombinant protein vaccine, SCTV01C in unvaccinated adults: A randomized, double-blinded, placebo-controlled, phase I clinical trial. Journal of infection. 86 (2), pp. 154-225. [Online].